New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - dimeticone 15%{relative} (350); light liquid paraffin 10%{relative}; zinc oxide 15%{relative} - topical cream - active: dimeticone 15%{relative} (350) light liquid paraffin 10%{relative} zinc oxide 15%{relative} excipient: cetostearyl alcohol dexpanthenol glycerol ceteareth-25 methyl hydroxybenzoate propyl hydroxybenzoate purified water xanthan gum

Australia - English - Department of Health (Therapeutic Goods Administration)

ego pharmaceuticals pty ltd - dimeticone 350, quantity: 150 mg/g - cream - excipient ingredients: self-emulsifying glyceryl monostearate; purified water; cetyl alcohol; light liquid paraffin; propyl hydroxybenzoate; glycerol; methyl hydroxybenzoate - helps protect the skin from water, chemicals and other external irritants. helps prevent dermatitis and dry skin. helps relieve the symptoms of eczema. helps prevent blisters and chafing during sport. helps to prevent bed sores. helps protecting skin and surrounding colostomy site. helps to protect traumatised skin from further irritation. helps prevent dribble and napkin rash.

Australia - English - Department of Health (Therapeutic Goods Administration)

ego pharmaceuticals pty ltd - dimeticone 350, quantity: 150 mg/g - lotion - excipient ingredients: propyl hydroxybenzoate; carbomer 934p; self-emulsifying glyceryl monostearate; glycerol; cetomacrogol 1000; cetyl alcohol; trolamine; purified water; methyl hydroxybenzoate; light liquid paraffin - helps protect the skin from water, chemicals and other external irritants. helps prevent dermatitis and dry skin. helps relieve the symptoms of eczema. helps prevent blisters and chafing during sport. helps to prevent bed sores. helps protecting skin and surrounding colostomy site. helps to protect traumatised skin from further irritation. helps prevent dribble and napkin rash.

Australia - English - Department of Health (Therapeutic Goods Administration)

ego pharmaceuticals pty ltd - dimeticone 350, quantity: 150 mg/g - cream - excipient ingredients: methyl hydroxybenzoate; cetyl alcohol; glycerol; liquid paraffin; purified water; propyl hydroxybenzoate; self-emulsifying glyceryl monostearate - helps protect the skin from water, chemicals and other external irritants. helps prevent dermatitis and dry skin. helps relieve the symptoms of eczema. helps prevent blisters and chafing during sport. helps to prevent bed sores. helps protecting skin and surrounding colostomy site. helps to protect traumatised skin from further irritation. helps prevent dribble and napkin rash.

Ireland - English - HPRA (Health Products Regulatory Authority)

ayrton saunders (ireland) limited - dimeticone 350; zinc oxide - cutaneous spray, suspension - 12.5%w/w + 1.04 percent weight/weight - zinc products

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - pancreatin 150mg (amylase 8,000 ph eur u, lipase 10,000 ph eur u, total protease 600 ph eur u.); pancreatin 150mg equivalent to amylase 8,000 ph eur u, lipase 10,000 ph eur u, total protease 600 ph eur u. - modified release capsule - 150 mg - active: pancreatin 150mg (amylase 8,000 ph eur u, lipase 10,000 ph eur u, total protease 600 ph eur u.) excipient: acetone dibutyl phthalate dimeticone gelatin hypromellose phthalate iron oxide black iron oxide red iron oxide yellow liquid paraffin macrogol 4000 propyl alcohol titanium dioxide active: pancreatin 150mg equivalent to amylase 8,000 ph eur u, lipase 10,000 ph eur u, total protease 600 ph eur u. excipient: cetyl alcohol dimeticone ferrosoferric oxide gelatin hypromellose phthalate iron oxide red iron oxide yellow macrogol 4000 sodium laurilsulfate titanium dioxide triethyl citrate - creon is indicated for the treatment of pancreatic exocrine insufficiency (pei) in paediatric and adult patients. pancreatic exocrine insufficiency is often associated with, but not limited to: · cystic fibrosis · chronic pancreatitis · post-pancreatectomy · post-gastrointestinal bypass surgery ,(e.g. billroth ii, gastroenterostomy) · ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm).

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 53.72 mg/ml (equivalent: cefaclor, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; tapioca starch; erythrosine; sucrose; flavour - aclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. aclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of aclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Australia - English - Department of Health (Therapeutic Goods Administration)

ego pharmaceuticals pty ltd - zinc oxide, quantity: 150 mg/g; light liquid paraffin, quantity: 100 mg/g; dimeticone 350, quantity: 150 mg/g - cream - excipient ingredients: dexpanthenol; propyl hydroxybenzoate; cetostearyl alcohol; xanthan gum; ceteareth-25; glycerol; purified water; methyl hydroxybenzoate - dermatitis including napkin rash, miliaria rubra (prickly heat), eczema, chafing.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 53.72 mg/ml (equivalent: cefaclor, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: methylcellulose; sodium lauryl sulfate; dimeticone 350; xanthan gum; tapioca starch; erythrosine; sucrose; flavour - ceclor is indicated for the treatment of the following types of infections caused by or likely to be caused by susceptible organisms: lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis, tonsillitis and otitis media. skin and skin structure infections. urinary tract infections including pyelonephritis and cystitis. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ceclor appears to be as effective as phenoxymethyl penicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of ceclor in the subsequent prevention of rheumatic fever are not available at present. 2. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - white soft paraffin 5%{relative} - lotion - 5 % - active: white soft paraffin 5%{relative} excipient: alkyl c12-15 benzoate carbomer cetomacrogol 1000 cetostearyl alcohol dichlorobenzyl alcohol dimeticone glycerol glyceryl monostearate methyl hydroxybenzoate polyoxyethylene stearyl ether propyl hydroxybenzoate purified water trolamine